Nasal decongestant is one of the categories of pharmaceutical drug that is used to cure nasal congestion in the upper respiratory tract. Common Nasal decongestant relieves congestion induce by the common cold, and uppermost respiratory infection or allergies. In some cases, Nasal decongestant relieves congestion which arises when the blood vessels sheathing the nose gets enlarged. Among all cases of rhinitis, hypersensitive rhinitis accounts for a broad proportion and is a common cause is congestion. For instance, in the last three decades, allergic rhinitis prevalence has been increasing globally. Besides, it is estimated that around 10% to 20% of the global population experience hypersensitive rhinitis in their lifetime. The disease is more common amongst pediatric and teen populations, as more than 80% of patients suffer from allergic rhinitis and also develop symptoms before the age of 20 years. Nasal decongestant treatment comprises of drug medications as well as surgical treatments such as corticosteroids, antibiotics, sinus irrigation, steroid nasal sprays, and endoscopic sinus surgery. Though the market of nasal decongestant is well equipped with various treatment options, still, a large number of people continue to struggle with disease symptoms as they prefer home remedies or Ayurvedic mediations which have low biological potency.
High level of pollution, extreme climate and nasal congestion due to asthma, these are some of the factors which are shooting up the nasal decongestant market. Global consumption of tobacco and low cure of hypersensitive rhinitis are the factors which drive the market of nasal decongestant rapidly in upcoming years. Moreover that ascending requirement of OTC nasal decongestant due to high demand for self-administration nasal medication.
The global market for muscle ointments is divided based on segmentation by drug type, dosage form, application, distribution channel and geography:
Segmentation by Drug Type
Segmentation by Dosage Form:
Segmentation by Application
Segmentation by Distribution Channel
The global nasal decongestant market is expanding in many different approaches and segmented based on drug type, application, dosage form and distribution channel. Expansion of the nasal decongestant market arises with the leading technologies development and online promotional and sales activities. For instance, in March 2019, Adapt pharma launched NARCANDirect.com for offering online service for buying the nasal decongestant sprays of the company. Same as in the year2018 McNeil launched new nasal decongestant spray which can use in the treatment of Hayfever.
Besides that the region with the low degree temperature carries the high number of paediatrics and geriatric patients with nasal complications so in corresponding territory demand of nasal decongestant market will shoot-up. Whereas Asia Pacific, North America and Europe are expected to contribute higher market value share in the global the nasal decongestant market.
As per the current nasal decongestant market events, topical drug administration into the nasal cavity has become a widely prescribed nasal decongestant form. In the nasal decongestant market, some of the combinations are available only with the doctor’s prescription whereas remaining all available at Over-the-counter (OTC). Whereas there are some special instructions for the nasal decongestant use which are prescribed by doctors.
Some of the top key players present in nasal decongestant market are GlaxoSmithKline plc. , Cipla Limited, Bayer AG, ADAPT Pharma, Inc., Aurena, INNOVUS PHARMACEUTICALS, INC., Novartis AG (Sandoz International GmbH), Iroko Pharmaceuticals Inc. (Egalet Corporation), Leeford Healthcare Limited, Mylan N.V., Sumitomo Dainippon Pharma (Sunovion Pharmaceuticals Inc.), Nephron Pharmaceuticals Corporation, Glenmark pharmaceutical ltd., Abbott laboratories, Micro labs limited, Lupin pharmaceutical Inc. and others.
The report on the nasal decongestant market covers exhaustive analysis on:
Regional analysis for the nasal decongestant market includes
Report on the nasal decongestant market highlights: